

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 October 2000 (26.10.2000)

PCT

(10) International Publication Number
WO 00/63361 A3(51) International Patent Classification⁷: C12N 15/10,
15/52, 9/10, 15/63, 15/90, C12P 19/62, C12R 1/465,
C07D 309/00, 313/04, 493/10, C07H 17/04, A61K 31/70,
A61P 31/00Apt. 4, San Francisco, CA 94112 (US). ASHLEY, Gary;
1102 Verdemar Drive, Alameda, CA 94502 (US).

(21) International Application Number: PCT/US00/10021

(74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster LLP, 3811 Valley Centre Drive, Suite 500, San Diego, CA 92130-2332 (US).

(22) International Filing Date: 12 April 2000 (12.04.2000)

(81) Designated States (*national*): AU, CA, JP.

(25) Filing Language: English

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).


(26) Publication Language: English

Published:— *With international search report.*(30) Priority Data:
60/129,731 16 April 1999 (16.04.1999) US(88) Date of publication of the international search report:
12 July 2001(71) Applicant: KOSAN BIOSCIENCES, INC. [US/US];
3832 Bay Center Place, Hayward, CA 94545 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: SANTI, Daniel, V.; 211 Belgrave Avenue, San
Francisco, CA 94117 (US). XUE, Qun; 1042 Irving Street,

(54) Title: A MULTI-PLASMID METHOD FOR PREPARING LARGE LIBRARIES OF POLYKETIDES AND NON-RIBOSOMAL PEPTIDES



(57) Abstract: A multiple-plasmid system for heterologous expression of polyketides facilitates combinatorial biosynthesis. The method can be extended to any modular polyketide synthase (PKS) or non-ribosomal peptide synthase (NRPS) and has the potential to produce thousands of novel natural products, including ones derived from further modification of the PKS or NRPS products by tailoring enzymes.

WO 00/63361 A3

INTERNATIONAL SEARCH REPORT

Int	tional Application No
PCT/US 00/10021	

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C12N15/10	C12N15/52	C12N9/10	C12N15/63	C12N15/90
	C12P19/62	C12R1/465	C07D309/00	C07D313/04	C07D493/10
	C07H17/04	A61K31/70	A61P31/00		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>C. RICHARD HUTCHINSON: "Microbial polyketide synthases: more and more prolific" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 7, 30 March 1999 (1999-03-30), pages 3336-3338, XP002151574 page 3338, left-hand column, paragraph 1</p> <p>---</p> <p style="text-align: center;">-/-</p>	1-3,5-8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

30 January 2001

Date of mailing of the international search report

02.2.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/10021

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 49315 A (KOSAN BIOSCIENCES INC ;UNIV LELAND STANFORD JUNIOR (US)) 5 November 1998 (1998-11-05) page 4, line 14 -page 5, line 19 page 6, line 14 -page 8, line 8 page 10, line 25 -page 11, line 18 page 17, line 8 -page 18, line 5 page 20, line 16 -page 22, line 16 page 25, line 24 -page 27, line 25; figures 6A-6H,12; examples 1-5; table 2 ---	1-8, 10-13,20
X	WO 97 02358 A (UNIV LELAND STANFORD JUNIOR ;UNIV BROWN RES FOUND (US)) 23 January 1997 (1997-01-23) page 7, line 25 -page 9, line 7 page 23, line 10 -page 29, line 10 page 35, line 5 -page 48, line 30; examples 1-11 ---	1-8,10, 11
X	WO 96 40968 A (UNIV LELAND STANFORD JUNIOR ;JOHN INNES CENTRE (GB)) 19 December 1996 (1996-12-19) page 5, line 5 -page 9, line 4 page 27, line 13 -page 32, line 35 page 37, line 3-35 examples 2,8; table 6 claim 17; figures 11,20,22 ---	1-8,10, 11
X	MCDANIEL ROBERT ET AL: "Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 5, 2 March 1999 (1999-03-02), pages 1846-1851, XP002143433 March 2, 1999 ISSN: 0027-8424 cited in the application the whole document ---	1-3,5-8, 10,11
X	KHOSLA C ET AL: "Generation of polyketide libraries via combinatorial biosynthesis" TRENDS IN BIOTECHNOLOGY,GB,ELSEVIER PUBLICATIONS, CAMBRIDGE, vol. 14, no. 9, 1 September 1996 (1996-09-01), pages 335-341, XP004035738 ISSN: 0167-7799 page 339, right-hand column -page 340; figure 5 ---	1-8,10, 11
	-/-	

INTERNATIONAL SEARCH REPORT

Int	tional Application No PCT/US 00/10021
-----	--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LIU L ET AL: "Biosynthesis of 2-nor-6-deoxyerythronolide B by rationally designed domain substitutions" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 119, no. 43, 29 October 1997 (1997-10-29), pages 10553-10554, XP002143432 ISSN: 0002-7863 the whole document</p> <p>---</p>	1-3,10, 11
X	<p>DONADIO S ET AL: "MODULAR ORGANIZATION OF GENES REQUIRED FOR COMPLEX POLYKETIDE BIOSYNTHESIS" SCIENCE, US, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 252, 3 May 1991 (1991-05-03), pages 675-679, XP002035890 ISSN: 0036-8075 the whole document</p> <p>---</p>	1-3,10, 11
X	<p>RUAN X ET AL: "Acyltransferase domain substitutions in erythromycin polyketide synthase yield novel erythromycin derivatives" JOURNAL OF BACTERIOLOGY, US, WASHINGTON, DC, vol. 179, no. 20, October 1997 (1997-10), pages 6416-6425, XP002117397 ISSN: 0021-9193 the whole document</p> <p>---</p>	1-3,10, 11
X	<p>KAO C M ET AL: "ENGINEERED BIOSYNTHESIS OF A COMPLETE MACROLACTONE IN A HETEROLOGOUS HOST" SCIENCE, US, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 265, no. 5171, 22 July 1994 (1994-07-22), pages 509-512, XP002073974 ISSN: 0036-8075 the whole document</p> <p>---</p>	1-8,10, 11
X	<p>XUE YONGQUAN ET AL: "A gene cluster for macrolide antibiotic biosynthesis in Streptomyces venezuelae: Architecture of metabolic diversity" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, US, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, vol. 95, no. 21, 13 October 1998 (1998-10-13), pages 12111-12116, XP002117399 ISSN: 0027-8424 the whole document</p> <p>---</p>	1-3

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/10021

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 05283 A (MENDEZ CARMEN ; SALAS JOSE A (ES); RAYNAL MARIE CECILE (FR); FROMEN) 4 February 1999 (1999-02-04) abstract page 10, line 24 -page 12, line 33 page 15, line 18 -page 16, line 12; example 31 ---	1-3,5-8
X	GRAZIANI E I ET AL: "Macrolide biosynthesis: a single cytochrome P450, PicK, is responsible for the hydroxylations that generate methymycin, neomethymycin, and picromycin in streptomyces venezuelae" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, GB, OXFORD, vol. 8, no. 22, 17 November 1998 (1998-11-17), pages 3117-3120, XP004143711 ISSN: 0960-894X the whole document ---	1-3
X	BETLACH M C ET AL: "Characterization of the macrolide P-450 hydroxylase from Streptomyces venezuelae which converts narbomycin to picromycin" BIOCHEMISTRY, US, AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 37, no. 42, 20 October 1998 (1998-10-20), pages 14937-14942, XP002117398 ISSN: 0006-2960 the whole document ---	1-3
X	OLANO C ET AL: "Analysis of a Streptomyces antibioticus chromosomal region involved in oleandomycin biosynthesis, which encodes two glycosyltransferases responsible for glycosylation of the macrolactone ring" MOLECULAR AND GENERAL GENETICS, DE, SPRINGER VERLAG, BERLIN, vol. 259, no. 3, 1 August 1998 (1998-08-01), pages 299-308, XP002096258 ISSN: 0026-8925 the whole document --- -/-	1-3

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/10021

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	QUIROS ET AL: "Biosynthesis of the macrolide oleandomycin by Streptomyces antibioticus" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 270, no. 31, 4 August 1995 (1995-08-04), pages 18234-18239, XP002096256 ISSN: 0021-9258 the whole document	1-3
A	SCHNEIDER A ET AL: "Targeted alteration of the substrate specificity of peptide synthetases by rational module swapping" MOLECULAR AND GENERAL GENETICS, DE, SPRINGER VERLAG, BERLIN, vol. 257, no. 3, February 1998 (1998-02), pages 308-318, XP002113933 ISSN: 0026-8925 the whole document	1,4
A	MARAHIEL M A ET AL: "Modular peptide synthetases involved in nonribosomal peptide synthesis" CHEMICAL REVIEWS, US, AMERICAN CHEMICAL SOCIETY, EASTON, vol. 97, no. 7, November 1997 (1997-11), pages 2651-2673, XP002133489 ISSN: 0009-2665 the whole document	1,4
P,X	TANG LI ET AL: "Cloning and heterologous expression of the epothilone gene cluster" SCIENCE, US, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 287, 28 January 2000 (2000-01-28), pages 640-642, XP002135841 ISSN: 0036-8075 the whole document	1-8
P,X	TANG L ET AL: "FORMATION OF FUNCTIONAL HETEROLOGOUS COMPLEXES USING SUBUNITS FROM THE PICROMYCIN, ERYTHROMYCIN AND OLEANDOMYCIN POLYKETIDE SYNTHASES" CHEMISTRY AND BIOLOGY, GB, CURRENT BIOLOGY, LONDON, vol. 7, no. 2, February 2000 (2000-02), pages 77-84, XP000909347 ISSN: 1074-5521 the whole document	1-8
		-/-

INTERNATIONAL SEARCH REPORT

Int	tional Application No
PCT/US 00/10021	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	XUE QUN ET AL: "A multiplasmid approach to preparing large libraries of polyketides." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 21, 12 October 1999 (1999-10-12), pages 11740-11745, XP002151575 Oct. 12, 1999 ISSN: 0027-8424 the whole document	1-20
E	WO 00 24907 A (KOSAN BIOSCIENCES INC) 4 May 2000 (2000-05-04) cited in the application page 3-24	1-3, 10-13, 18,20
E	WO 00 26349 A (KOSAN BIOSCIENCES INC) 11 May 2000 (2000-05-11) page 3, line 5 -page 6, line 7 page 31, line 10 -page 35, line 29 page 39, line 20 -page 40, line 21 page 47, line 28 -page 53, line 33 page 58, line 19 -page 60, line 12 page 62, line 8 -page 64, line 8	1-8
E	WO 00 31247 A (KOSAN BIOSCIENCES INC) 2 June 2000 (2000-06-02) page 2, line 1-5 page 3, line 17 -page 5, line 17 page 7, line 20 -page 11, line 21 page 14, line 5 -page 16, line 13 page 22, line 6 -page 23, line 10 page 42, line 4 -page 48, line 25	1-8
E	WO 00 52152 A (STACHELHAUS TORSTEN ;KONZ DIRK (DE); MOOTZ HENNING (DE); MARAHIEL) 8 September 2000 (2000-09-08) page 1-4	1,4

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-9

A method for expressing a (modified) polyketide or non-ribosomal peptide in a host cell employing a multiplicity of recombinant vectors to transform a host cell.

2. Claims: 10-13 partially and 14-20 completely

Polyketides with formulas 29-43 (14-membered macrolactones) selected from the group consisting of compounds shown in Figure 3.

3. Claims: 10-13 partially

Polyketides with formulas 45-59 (structures 44-48 are 12-membered lactones) selected from the group consisting of compounds shown in Figure 3

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 10,11

Present claims 10 and 11 relate to compounds nos. 29-43 and 45-59 as depicted in Figure 3 from the application, however Figure 3 discloses compounds nos. 1-48. Thus the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for such compounds. In the present case, claims 10-11 so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claim scope is impossible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

...nternational application No.
PCT/US 00/10021

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 10, 11 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-9, 12-20

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int.	International Application No
	PCT/US 00/10021

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9849315	A 05-11-1998	AU 7172298 A			24-11-1998
		EP 0979286 A			16-02-2000
		US 6117659 A			12-09-2000
WO 9702358	A 23-01-1997	AU 706445 B			17-06-1999
		AU 6542696 A			05-02-1997
		CA 2226221 A			23-01-1997
		EP 0836649 A			22-04-1998
		JP 10510167 T			06-10-1998
		NZ 313383 A			30-08-1999
WO 9640968	A 19-12-1996	US 5712146 A			27-01-1998
		AU 703920 B			01-04-1999
		AU 6157596 A			30-12-1996
		CA 2224104 A			19-12-1996
		EP 0871760 A			21-10-1998
		NZ 310729 A			29-09-1999
		US 6077696 A			20-06-2000
		US 5962290 A			05-10-1999
WO 9905283	A 04-02-1999	FR 2766496 A			29-01-1999
		FR 2786200 A			26-05-2000
		EP 1032679 A			06-09-2000
WO 0024907	A 04-05-2000	AU 1447700 A			15-05-2000
WO 0026349	A 11-05-2000	AU 1125400 A			22-05-2000
WO 0031247	A 02-06-2000	AU 1737700 A			13-06-2000
WO 0052152	A 08-09-2000	DE 19909146 A			28-09-2000
		AU 3425700 A			21-09-2000



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :	A2	(11) International Publication Number: WO 00/63361
C12N 15/10, 15/52, 9/10, 15/63, 15/90, C12P 19/62, C12R 1/465		(43) International Publication Date: 26 October 2000 (26.10.00)

(21) International Application Number: PCT/US00/10021

(22) International Filing Date: 12 April 2000 (12.04.00)

(30) Priority Data:
60/129,731 16 April 1999 (16.04.99) US

(71) Applicant: KOSAN BIOSCIENCES, INC. [US/US]; 3832 Bay Center Place, Hayward, CA 94545 (US).

(72) Inventors: SANTI, Daniel, V.; 211 Belgrave Avenue, San Francisco, CA 94117 (US). XUE, Qun; 1042 Irving Street, Apt. 4, San Francisco, CA 94112 (US). ASHLEY, Gary; 1102 Verdeman Drive, Alameda, CA 94502 (US).


(74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster LLP, 2000 Pennsylvania Avenue N.W., Washington, DC 20006-1888 (US).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: A MULTI-PLASMID METHOD FOR PREPARING LARGE LIBRARIES OF POLYKETIDES AND NON-RIBOSOMAL PEPTIDES



(57) Abstract

A multiple-plasmid system for heterologous expression of polyketides facilitates combinatorial biosynthesis. The method can be extended to any modular polyketide synthase (PKS) or non-ribosomal peptide synthase (NRPS) and has the potential to produce thousands of novel natural products, including ones derived from further modification of the PKS or NRPS products by tailoring enzymes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

Title

A Multi-Plasmid Method for Preparing Large Libraries of Polyketides and Non-Ribosomal Peptides

5

Reference to Government Funding

This invention was supported in part by SBIR grant 1R43-GM56575-01. The U.S. government has certain rights in this invention.

Field of the Invention

10 The present invention provides recombinant DNA compounds and host cells containing novel polyketide synthase (PKS) genes and novel polyketides. The invention relates to the fields of chemistry, medicinal chemistry, human and veterinary medicine, molecular biology, pharmacology, agriculture, and animal husbandry.

15

Background of the Invention

Polyketides are structurally diverse natural products that include important therapeutic agents used as antibacterials (erythromycin), immunosuppressants (FK506), cholesterol-lowering agents (lovastatin), and 20 others (see Katz *et al.*, 1993, Polyketide synthesis: prospects for hybrid antibiotics, *Annu. Rev. Microbiol.* **47**: 875-912, incorporated herein by reference). Currently, there are about 7,000 identified polyketides, but this represents only a small fraction of what nature is capable of producing.

DNA sequencing of genes encoding several of the enzymes that produce 25 type 1 modular polyketide synthases (PKSs) has revealed the remarkably logical organization of these multifunctional enzymes (see Cortes *et al.*, 1990, An unusually large multifunctional polypeptide in the erythromycin-producing polyketide synthase of *Saccharopolyspora erythraea*, *Nature* **348**: 176-178; Donadio *et al.*, 1991, Modular organization of genes required for complex polyketide 30 biosynthesis, *Science* **252**: 675-679; Schwecke *et al.*, 1995, The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin, *Proc. Natl. Acad. Sci.*

USA 92: 7839-7843; and August *et al.*, 1998, Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the *rif* biosynthetic gene cluster of *Amycolatopsis mediterranei* S699, *Chem Biol* 5: 69-79, each of which is incorporated herein by reference). The application of innovative combinatorial techniques to this genetic organization has prompted the generation of novel natural products, by adding, deleting, or exchanging domains or entire modules. See U.S. Patent Nos. 5,672,491; 5,712,146; 5,830,750; 5,843,718; 5,962,290; and 6,022,731, each of which is incorporated herein by reference. It would be advantageous to have a practical combinatorial biosynthesis technology that could achieve and perhaps exceed the diversity of modular polyketide structures thus far revealed in nature.

The known modular PKSs have a linear organization of modules, each of which contains the activities needed for one cycle of polyketide chain elongation, as illustrated for 6-deoxyerythronolide B synthase (DEBS) in Fig. 1A. The minimal module contains a ketosynthase (KS), an acyltransferase (AT), and an acyl carrier protein (ACP) that together catalyze a 2-carbon extension of the chain. The specificity of the AT for either malonyl or an alpha-alkyl malonyl CoA determines which 2-carbon extender is used, and thus the nature of the alkyl substituent at the alpha-carbon of the growing polyketide chain. After each 2-carbon unit condensation, the oxidation state of the beta-carbon is either retained as a ketone, or modified to a hydroxyl, methenyl, or methylene group by the presence a ketoreductase (KR), a KR + a dehydratase (DH), or a KR + DH + an enoyl reductase (ER), respectively. In effect, the AT specificity and the composition of catalytic domains within a module serve as a "code" for the structure of each 2-carbon unit. The order of the modules in a PKS specifies the sequence of the distinct 2-carbon units, and the number of modules determines the size of the polyketide chain.

The remarkable structural diversity of polyketides (see O'Hagan, *The Polyketide Metabolites*; Ellis Horwood, Chichester, 1991, incorporated herein by reference) is governed by the combinatorial possibilities of arranging modules

containing the various catalytic domains, the sequence and number of modules, and the post-PKS "tailoring enzymes" that accompany the PKS genes. The direct correspondence between the catalytic domains of modules in a PKS and the structure of the resulting biosynthetic product allows rational modification of
5 polyketide structure by genetic engineering.

Over the past several years, examples of modifying each of the elements that code for polyketide structure has been accomplished (see Kao *et al.*, 1996, Evidence for two catalytically independent clusters of active sites in a functional modular polyketide synthase, *Biochemistry* 35: 12363-12368; Liu *et al.*, 1997,
10 Biosynthesis of 2-nor-6-deoxyerythronolide B by rationally designed domain substitution, *J. Am. Chem. Soc.* 119: 10553-10554; McDaniel *et al.*, 1997, Gain-of-function mutagenesis of a modular polyketide synthase, *J. Am. Chem. Soc.* 119:
4309-4310; Marsden *et al.*, 1998, Engineering broader specificity into an antibiotic-producing polyketide synthase, *Science* 279: 199-202; and Jacobsen *et al.*, 1997,
15 Precursor-directed biosynthesis of erythromycin analogs by an engineered polyketide synthase, *Science* 277: 367-369, each of which is incorporated herein by reference).

Recently, a combinatorial library of over 50 novel polyketides was prepared by systematic modification of DEBS, the PKS that produces the
20 macrolide aglycone precursor of erythromycin (see U.S. patent application Serial No. 09/429,349, filed 28 Oct. 1999; PCT patent application US99/24483, filed 20 Oct. 1999; and McDaniel *et al.*, 1999, Multiple genetic modification of the erythromycin gene cluster to produce a library of novel "unnatural" natural products, *Proc. Natl. Acad. Sci. USA* 96: 1846-1851, each of which is incorporated
25 herein by reference). With a single plasmid containing the *eryA1*, -*AII* and -*AIII* genes encoding the three DEBS subunits, ATs and beta-carbon processing domains were substituted by counterparts from the rapamycin PKS (see Schwecke *et al.*, 1995, *supra*) that encode alternative substrate specificities and beta-carbon processing activities. The approach used was to develop single "mutations", then
30 sequentially combine the single mutations to produce multiple changes in the

PKS. It was observed that when two or more single PKS mutants were functional, there was a high likelihood that combinations would also produce the expected polyketide. Although this strategy provided high assurance that the multiple mutants would be productive, the production of each polyketide required a 5 separate engineering. Thus, if X mutants of *eryAI*, Y mutants of *eryAII*, and Z mutants at *eryAIII* were prepared, X+Y+Z separate experiments were required to produce that same number of polyketides. Clearly, the preparation of very large libraries by this approach is laborious.

Another strategy for preparing large numbers of polyketides is by random 10 digestion-religation leading to "mutagenesis" of the domains or modules of a mixture of PKS genes, including the refinements embodied in the DNA shuffling method (see Patten *et al.*, 1997, Applications of DNA shuffling to pharmaceuticals and vaccines, *Curr. Op. Biotechnol.* 8: 724-733, incorporated herein by reference). The expected low probability of assembling an active PKS by such an approach, 15 however, would demand an extraordinary analytical effort (in the absence of a biological selection) to detect clones that produced polyketides within the much larger number of clones that are non-producers.

There remains a need for practical approaches to create large libraries of 20 polyketides, non-ribosomal peptides, and mixed polyketides/non-ribosomal peptides.

Summary of the Invention

The present invention provides a method for expressing a polyketide or 25 non-ribosomal peptide in a host cell employing a multiplicity of recombinant vectors, which may be integrative or freely replicating. Each of the multiplicity of vectors encodes a portion of the polyketide synthase or non-ribosomal peptide synthase that produces the polyketide or non-ribosomal peptide. In one embodiment, at least one of the multiplicity of vectors encodes one or more proteins that further modify the polyketide or non-ribosomal peptide produced.

In a preferred embodiment, the vectors replicate in and/or integrate into the chromosome of a *Streptomyces* host cell. Preferred integrating vectors include vectors derived from pSET152 and pSAM2. Preferred replicating vectors include those containing a replicon derived from SCP2* or pJV1.

5 In another embodiment, the present invention provides novel polyketides. Such novel polyketides include those shown in Figure 3 as compound nos. 29-43 and 45-59. Other novel polyketides of the invention include the polyketides obtainable by hydroxylation and/or glycosylation of compounds 29-43 and 45-59. Preferred compounds of the invention include those 14-membered macrolactones
10 with a C-6 and/or C-12 hydroxyl and/or a C-3 and/or C-5 glycosyl, including but not limited to those with a desosaminyl residue at C-5 and a cladinosyl residue at C-3.

These and other embodiments, modes, and aspects of the invention are described in more detail in the following description, the examples, and claims set
15 forth below.

Description of the Drawings

Figure 1 shows wild-type and mutant forms of the *eryA* genes and DEBS proteins. Part A depicts the *eryAI*-*eryAIII* genes and proteins as broad arrows oriented in the direction of transcription with the domains in modules 1 to 6 of DEBS1-DEBS3 indicated by the symbols defined herein. The first substrate, propionyl-CoA, is attached to the loading domain ACP and (2S)-2-methylmalonyl-CoA to the module 2 ACP. Then, a decarboxylative condensation between the propionate and methylmalonate takes place followed by reduction of
20 the incipient beta-ketone to form the intermediate shown attached to the ACP of module 2. This intermediate is transferred to the ACP of module 3, and the sequence of reactions is repeated at each of the other modules with or without ketone reduction, dehydration, or double bond reduction to form the linear 21-carbon polyketide attached to the ACP of module 6. The linear polyketide then is
25 cyclized and released as 6-deoxyerythronolide B (6dEB). Part B depicts
30

replacement of the one or more of the domains in DEBS1, DEBS2, or DEBS3 with one of the three rap (rapamycin) PKS domains or cassettes, or deletion of the KR. This results in the corresponding functional group changes shown at one or more of the positions of 6dEB.

5 Figure 2 shows an illustrative three-plasmid expression system for *eryA* genes. In each vector, the *eryA* gene is expressed under the control of the upstream *actI* promoter and *actII-ORF4* gene as previously described (see Ziermann *et al.*, 2000, A two-vector system for the production of recombinant polyketides in *Streptomyces*, *J. Ind. Microbiol. & Biotech.* **24**: 46-50; and Kao *et al.*,
10 1994, Engineered biosynthesis of a complete macrolactone in a heterologous host, *Science* **265**: 509-512, each of which is incorporated herein by reference). To
facilitate construction of the various *eryA* mutations, a *SpeI* site (ACTAGT) was
introduced at nt 10366-10371 of the *eryAI* ORF by making D3455T and A3456S
mutations (see Kao *et al.*, 1995, Manipulation of macrolide ring size by directed
15 mutagenesis of a modular polyketide synthase, *J. Am. Chem. Soc.* **117**: 9105-9106,
incorporated herein by reference) in pKOS025-179. This change enables insertion
of the mutated gene segment between the *PacI* site and the *SpeI* site of pKOS025-
179. After the replacement of the 6-kb fragment between the *Ascl* sites in *eryAII* (nt
1213 and nt 7290) with a 6-kb *Ascl* fragment containing a specific AT substitution
20 in an intermediate plasmid, the resulting *PacI-XbaI* fragment containing the
mutant *eryAII* gene was inserted into pKOS025-143. All *eryAIII* mutants were
constructed by replacing the segment in pKOS010-153 between the unique *BglII*
site at nt 251 and the *EcoRI* site (nt 9290) that overlaps the stop codon.

Figure 3 shows structures of macrolactones produced by *Streptomyces*
25 *lividans* strains containing assorted combinations of three plasmids (Fig. 2 and
Table 1). The positions in 6dEB (1) that are altered correspond to the genetic
characteristics of modules 2, 3, 5 and 6 of DEBS, as illustrated in Fig. 1A and Fig. 2,
and listed in Table 1. Structures 1 - 40 and 49 - 56 are 14-membered lactones, and
structures 44 to 48 are 12-membered lactones. Compounds 49 - 59 with the C13

propyl group were produced by mutational biosynthesis with the *eryA1* KS1° null allele.

Detailed Description of the Invention

5 The present invention provides methods and reagents for using multiple recombinant DNA vectors to produce polyketides in recombinant host cells. In an illustrative embodiment, a three-plasmid system for heterologous expression of 6-deoxyerythronolide B synthase (DEBS) is provided to facilitate combinatorial biosynthesis of polyketides made by type I modular polyketide synthases (PKSs).

10 The *eryA* PKS genes encoding the three DEBS subunits were individually cloned into three compatible *Streptomyces* vectors carrying mutually selectable antibiotic resistance markers. A strain of *Streptomyces lividans* transformed with all three plasmids produced 6-deoxyerythronolide B at a level similar to that of a strain transformed with a single plasmid containing all three genes.

15 The utility of this system in combinatorial biosynthesis was demonstrated through production of a library of modified polyketide macrolactones, using versions of each plasmid constructed to contain defined mutations. Combinations of these vector sets were introduced into *Streptomyces lividans*, resulting in strains producing a wide range of 6-deoxyerythronolide B analogs. This method can be applied to any modular PKS or non-ribosomal peptide synthase (NRPS) and has the potential to produce thousands of novel natural products, including ones derived from further modification of the PKS or NRPS products by tailoring enzymes.

20 Thus, in one aspect, the present invention provides a method for using multiple (two, three, four, or more) recombinant DNA vectors, each encoding a portion of a PKS, NRPS, or tailoring enzyme, to produce a polyketide or non-ribosomal peptide or a mixed polyketide/non-ribosomal peptide in a host cell. In one embodiment, the vectors in combination encode a naturally occurring PKS or NRPS and the corresponding natural product is produced. In another embodiment, the vectors in combination encode naturally occurring proteins from two or more different naturally occurring PKS or NRPS. In another embodiment,

at least one of the vectors encodes a protein not found in nature, having been altered by recombinant DNA methodology to change its structure and function.

In one embodiment, the present invention provides a method for creating a polyketide library that enables the production of large libraries of polyketides

- 5 while retaining the high probability of obtaining productive clones by combining PKS mutations known to be productive. The principle involves cloning mutants of individual open reading frames (ORFs) of a PKS on separate compatible plasmids, then coexpressing the separate ORFs in a suitable host to produce the PKS. Using this multiple plasmid approach, with X mutants of ORF 1, Y mutants of ORF 2,
- 10 and Z mutants of ORF 3, for instance, a combinatorial library of $X \times Y \times Z$ mutants can be achieved expeditiously.

DEBS was chosen to illustrate this multiple plasmid approach. The DEBS PKS consists of three >280 kD protein subunits, each containing two modules, that are assembled into the complete PKS complex (see Donadio *et al.*, 1991, *supra*).

- 15 With the two possible AT domains and the four possible beta-keto modifications, i.e. eight at each module, therefore $8 \times 8 = 64$ permutations for the two modules are possible in each DEBS subunit. Constructing the mutations in each DEBS ORF separately would require that 64 manipulations be carried out on each gene, or a total of 192 such manipulations. However, by co-transforming a host strain with
- 20 three plasmids, each bearing the 64 permutations of a different DEBS subunit, one could generate the mutant PKSs necessary to achieve, in theory, a library of 262,144 polyketides (64^3), as 6-deoxyerythronolide B (6dEB) analogs (Fig. 1A). In contrast, the same number of mutagenesis experiments performed in a single plasmid system would theoretically yield only 192 polyketides.

- 25 The successful implementation of this multiple plasmid strategy requires that the DEBS subunits translated from three different mRNAs faithfully interact to give the active PKS. Some indication that this would be the case was provided by *in vitro* experiments that showed that reconstitution of the isolated DEBS1-DEBS2 complex with DEBS3 forms a functional PKS (see Pieper *et al.*, 1995, Cell-30 free synthesis of polyketides by recombinant erythromycin polyketide synthases,

Nature 378: 263-266, incorporated herein by reference). Further, it was recently demonstrated that coexpression of the three subunits of DEBS from two plasmids produced active PKS *in vivo* (see Ziermann *et al.*, 2000, *supra*). The present invention can be applied to any PKS or NRPS, including but not limited to the 5 PKS enzymes, including the KS1 null mutation containing versions, that synthesize oleandolide and megalomicin (see U.S. patent application Serial Nos. 60/158,305, filed 8 Oct. 1999 and 09/428,517, filed 28 Oct. 1999, and PCT application No. US99/24478, filed 22 Oct. 1999, each of which is incorporated herein by reference).

10 The method in one embodiment requires at least three vectors that can be separately introduced into a *Streptomyces* or other suitable host strain and concomitantly express functional PKS subunits. Two such vectors are preferred for such purposes: the autonomously replicating SCP2*-based plasmid pRM1 (see Kao *et al.*, 1994, Engineered biosynthesis of a complete macrolactone in a heterologous host, *Science* 265: 509-512, and U.S. Patent No. 6,022,731, each of 15 which is incorporated herein by reference) and the integrating bacteriophage phiC31-based plasmid pSET152 (see Bierman *et al.*, 1992, Plasmid cloning vectors for the conjugal transfer of DNA from *Escherichia coli* to *Streptomyces* spp., *Gene* 116: 43-49, incorporated herein by reference). Several additional plasmids have 20 been tested as described herein and can be used in accordance with the present invention.

Each of these additional plasmids was tested using constructs that contained identical configurations of an *eryA* gene downstream of the *Streptomyces coelicolor actI* promoter and *actII*-ORF4 transcriptional activator as described (see 25 Ziermann *et al.*, 2000, *supra*). Plasmid pB45, a high copy replicating plasmid possessing the pJV1 origin (see Servin-Gonzalez *et al.*, 1995, Sequence and functional analysis of the *Streptomyces phaeochromogenes* plasmid pJV1 reveals a modular organization of *Streptomyces* plasmids that replicate by rolling circle, *Microbiology* 141: 2499-2510, incorporated herein by reference) carrying *eryAII* was 30 introduced into *S. lividans* harboring *eryAI* on pRM1 and *eryAIII* in the pSET152

integration site; less than 0.1 mg/L of 6dEB was produced in this system compared with 50 mg/L for the single plasmid system (see Kao *et al.*, 1994, *supra*).

The multiple vectors used in the present method can include two or more different vectors that share the same origin of replication. For example, two

- 5 SCP2*-type plasmids carrying different antibiotic markers can coexist and express PKS subunits in a *Streptomyces* sp., as has been reported using high-copy number plasmids (see Rajgarhia *et al.*, 1997, *Minimal Streptomyces* sp. strain C5 daunorubicin polyketide biosynthesis genes required for aklanonic acid biosynthesis, *J. Bacteriol.* 179: 2690-2696, incorporated herein by reference). Co-
10 transformation of *S. lividans* with *eryAIII/pSET-apm*, *eryAI/pRM1-tsr* and *eryAII/pRM1-hyg* (Fig. 2) yielded a strain that also produced 50 mg/L of 6dEB. Further, after over 24 generations under double antibiotic selection, both replicating plasmids could be rescued by standard procedures with unchanged restriction maps (see Hopwood *et al.*, 1985, *Genetic Manipulation of Streptomyces. A
15 laboratory manual*. John Innes Foundation, Norwich, incorporated herein by reference).

- 15 The multiple vectors of the present invention can include two or more different integrating vectors as well. For example, the *eryAII* gene was cloned into a pSAM2 site-specific integrating plasmid (see Smokvina *et al.*, 1990, Construction of a series of pSAM2-based integrative vectors for use in *Actinomycetes*, *Gene* 94: 53-59, incorporated herein by reference). Sequential transformation of *Streptomyces lividans* with *eryAIII/pSET-apm*, *eryAII/pSAM-hyg* and *eryAI/pRM1-tsr* provided a strain that produced 40-50 mg/L of 6dEB. A potential advantage of this system over the two-replicating vector system is that it requires one fewer antibiotic, and avoids potential problems in maintaining two plasmids containing the same *ori* in a *Streptomyces* host (see Baltz, 1997, *Molecular genetic approaches to yield improvement in Actinomycetes, Biotechnology of Antibiotics*, 2nd. Edition: pp. 49-62, incorporated herein by reference). However, as shown herein, the two SCP2*-based plasmids and the pSET-derived vector can also be used.
20
25

Thus, the invention can be practiced with a wide variety of expression vectors for use in *Streptomyces*. The replicating expression vectors of the present invention include, for example and without limitation, those that comprise an origin of replication from a low copy number vector, such as SCP2* (see

- 5 Hopwood *et al.*, *Genetic Manipulation of Streptomyces: A Laboratory manual* (The John Innes Foundation, Norwich, U.K., 1985); Lydiate *et al.*, 1985, *Gene* 35: 223-235; and Kieser and Melton, 1988, *Gene* 65: 83-91, each of which is incorporated herein by reference), SLP1.2 (Thompson *et al.*, 1982, *Gene* 20: 51-62, incorporated herein by reference), and pSG5(ts) (Muth *et al.*, 1989, *Mol. Gen. Genet.* 219: 341-348, and
- 10 Bierman *et al.*, 1992, *Gene* 116: 43-49, each of which is incorporated herein by reference), or a high copy number vector, such as pIJ101 and pJV1 (see Katz *et al.*, 1983, *J. Gen. Microbiol.* 129: 2703-2714; Vara *et al.*, 1989, *J. Bacteriol.* 171: 5782-5781; and Servin-Gonzalez, 1993, *Plasmid* 30: 131-140, each of which is incorporated herein by reference). High copy number vectors are, however, generally not
- 15 preferred for expression of large genes or multiple genes. For non-replicating and integrating vectors and generally for any vector, it is useful to include at least an *E. coli* origin of replication, such as from pUC, p1P, p1I, and pBR. For phage based vectors, the phage phiC31 and its derivative KC515 can be employed (see Hopwood *et al.*, *supra*). Also, plasmid pSET152, plasmid pSAM, plasmids pSE101
- 20 and pSE211, all of which integrate site-specifically in the chromosomal DNA of *S. lividans*, can be employed for purposes of the present invention.

Moreover, a wide variety of selectable markers can be employed in the *Streptomyces* recombinant expression vectors of the invention. These include antibiotic resistance conferring genes selected from the group consisting of the

- 25 *ermE* (confers resistance to erythromycin and lincomycin), *tsr* (confers resistance to thiostrepton), *aadA* (confers resistance to spectinomycin and streptomycin), *aacC4* (confers resistance to apramycin, kanamycin, gentamicin, geneticin (G418), and neomycin), *hyg* (confers resistance to hygromycin), and *vph* (confers resistance to viomycin) resistance conferring genes. Alternatively, several polyketides are

naturally colored, and this characteristic can provide a built-in marker for identifying cells.

An illustrative library of the present invention was constructed. The library was composed of vectors encoding three single mutations in *eryAI* (module 2), one in *eryAII* (module 3), and seven in *eryAIII* (modules 5 or 6) as well as wild-type ORFs, a KS1 null mutant, and a module 6 deletion, as shown in Table 1, below. To facilitate cloning, vectors were prepared that contained restriction sites that allowed transfer of DNA cassettes from previously prepared mutant *eryA* genes (see McDaniel *et al.*, 1999, *supra*, and Fig. 2). Fourteen of these expression vectors, comprising the three wild-type and eleven mutant ORFs were constructed by cassette transfers from plasmids previously prepared in the single plasmid system.

Table 1

Genotype of the plasmids containing DEBS genes ^a			
Vector:	pKOS021	pKOS025	pKOS010
Gene:	<i>eryAI</i> (DEBS1)	<i>eryAII</i> (DEBS2)	<i>eryAIII</i> (DEBS3)
Module:	1	3	5 6
1. wild-type			
20	2. AT-> ^b rapAT2		
	3. KR->rapDH/KR4		
	4. KR->rapDH/ER/KR1		
	5. KS1 ^c		
6. wild-type			
25	7. AT3->rapAT2		
8. wild-type			
	9. AT->rapAT2		
	10. KR->AT/ACP linker		
	11. KR->rapDH/KR4		
	12. KR->rapDH/ER/KR1		
	13. module 5 + TE ^d		
14. AT->rapAT2			
30	15. KR->AT/ACP linker		
	16. KR->rapDH/KR4		

^a The plasmids with mutant DEBS genes were constructed by cloning the specified DNA segments into one of the three vectors shown in Fig. 2.

^b The arrow signifies that the wild-type domain was replaced with the one indicated.

40 ^c The Cys729Ala null allele was created by site-specific mutagenesis.

^d Module 6 was deleted to fuse its TE to the ACP of module 5.

In *eryAI*, module 2 was modified by replacing the AT by rapAT2 (the AT domain of module 2 of the rapamycin PKS), and the KR by rapDH/KR4 (the DH and KR domains of module 4 of the rapamycin PKS) or rapDH/ER/KR1 (the DH, KR, and ER domains of module 1 of the rapamycin PKS). In *eryAII*, the AT of 5 module 3 was replaced by rapAT2; in *eryAIII*, module 5 was modified by replacing the AT by rapAT2, and the KR by rapDH/KR4 or rapDH/ER/KR1 or the AT/ACP linker that eliminates the *ery* module 5 KR activity. Also, in module 10 6 the AT was replaced with rapAT2, and the KR by rapDH/KR4 or the AT/ACP linker. The consequence of introducing each of these rapamycin PKS gene cassettes into DEBS is shown in Fig. 1B; at a given alpha-position in the growing polyketide carbon chain, a methyl group can be removed, or a beta-hydroxyl can be changed to a ketone or removed by dehydration to produce a double bond, or the double bond resulting from dehydration can then be reduced to a methylene group.

The approach employed was to first introduce the eight *eryAIII* variants 15 individually into the pSET integration site of *S. lividans*, then to cotransform the resulting strains individually with each of four *eryAI* variants on SCP2*-*tsr* vectors and two *eryAII* variants on SCP2*-*hyg* vectors. Thus, from the 14 vectors prepared, 64 triple transformants were obtained. Recombinant cells were grown under 20 appropriate antibiotic selection, and extracts analyzed for polyketide production by LC/MS. Of the 64 triple transformants, 46 (72%) produced detectable levels of one or more polyketides under the test conditions employed (Fig. 3), and 43 different polyketides were produced. These included 6dEB (1), and products arising from 11 single (2-12), 26 double (13-38) and five (39-43) triple mutants of 25 DEBS. Twenty-eight (1-28) of the 43 polyketides produced have been previously prepared using the single-plasmid system. Fifteen (29-43) were novel polyketides readily identifiable by mass spectra and correspondence to the products expected based on the cassettes used in the mutagenesis.

In one aspect, the present invention provides these novel polyketides. 30 These novel polyketides can be further modified by tailoring enzymes, including

the tailoring enzymes of *Saccharopolyspora erythraea*. There are a wide variety of diverse organisms that can modify macrolide aglycones to provide compounds with, or that can be readily modified to have, useful activities. For example, *Saccharopolyspora erythraea* can convert 6-dEB or derivatives thereof to a variety of useful compounds. The erythronolide 6-dEB is converted by the *eryF* gene product to erythronolide B, which is, in turn, glycosylated by the *eryB* gene product to obtain 3-O-mycarosylerythronolide B, which contains L-mycarose at C-3. The enzyme *eryC* gene product then converts this compound to erythromycin D by glycosylation with D-desosamine at C-5. Erythromycin D, therefore, differs from 6-dEB through glycosylation and by the addition of a hydroxyl group at C-6. Erythromycin D can be converted to erythromycin B in a reaction catalyzed by the *eryG* gene product by methylating the L-mycarose residue at C-3. Erythromycin D is converted to erythromycin C by the addition of a hydroxyl group at C-12 in a reaction catalyzed by the *eryK* gene product. Erythromycin A is obtained from erythromycin C by methylation of the mycarose residue in a reaction catalyzed by the *eryG* gene product. The aglycone compounds provided by the present invention, such as, for example, the compounds produced in *Streptomyces lividans*, can be provided to cultures of *S. erythraea* and converted to the corresponding derivatives of erythromycins A, B, C, and D. To ensure that only the desired compound is produced, one can use an *S. erythraea* *eryA* mutant that is unable to produce 6-dEB but can still carry out the desired conversions (Weber *et al.*, 1985, *J. Bacteriol.* 164(1): 425-433). Also, one can employ other mutant strains, such as *eryB*, *eryC*, *eryG*, and/or *eryK* mutants, or mutant strains having mutations in multiple genes, to accumulate a preferred compound. The conversion can also be carried out in large fermentors for commercial production.

Moreover, there are other useful organisms that can be employed to hydroxylate and/or glycosylate the compounds of the invention. As described above, the organisms can be mutants unable to produce the polyketide normally produced in that organism, the fermentation can be carried out on plates or in large fermentors, and the compounds produced can be chemically altered after

fermentation. Thus, *Streptomyces venezuelae*, which produces picromycin, contains enzymes that can transfer a desosaminyl group to the C-5 hydroxyl and a hydroxyl group to the C-12 position. In addition, *S. venezuelae* contains a glucosylation activity that glucosylates the 2'-hydroxyl group of the desosamine sugar. This latter modification reduces antibiotic activity, but the glucosyl residue is removed by enzymatic action prior to release of the polyketide from the cell. Another organism, *S. narbonensis*, contains the same modification enzymes as *S. venezuelae*, except the C-12 hydroxylase. Thus, the present invention provides the compounds produced by hydroxylation and glycosylation of the macrolide aglycones of the invention by action of the enzymes endogenous to *S. narbonensis* and *S. venezuelae*.

Other organisms suitable for making compounds of the invention include *Micromonospora megalomicea*, which produces megalomicin A. Megalomicin A contains the complete erythromycin C structure, and its biosynthesis also involves the additional formation of megosamine (L-rhodosamine) and its attachment to the C-6 hydroxyl, followed by acylation of the C-3''' and(or) C-4''' hydroxyls as the terminal steps. Other organisms useful in converting the aglycones of the present invention to modified compounds include *Streptomyces antibioticus*, *S. fradiae*, and *S. thermotolerans*. *S. antibioticus* produces oleandomycin and contains enzymes that hydroxylate the C-6 and C-12 positions, glycosylate the C-3 hydroxyl with oleandrose and the C-5 hydroxyl with desosamine, and form an epoxide at C-8-C-8a. *S. fradiae* contains enzymes that glycosylate the C-5 hydroxyl with mycaminose and then the 4'-hydroxyl of mycaminose with mycarose, forming a disaccharide. *S. thermotolerans* contains the same activities as *S. fradiae*, as well as acylation activities. Thus, the present invention provides the compounds produced by hydroxylation and glycosylation of the macrolide aglycones of the invention by action of the enzymes endogenous to *S. antibioticus*, *S. fradiae*, and *S. thermotolerans*. Moreover, these and other tailoring enzymes can be cloned and incorporated into one or more of the multiple vectors used in

accordance with the methods of the present invention to create libraries of modified polyketide compounds.

The resulting compounds can be further modified by synthetic chemistry, i.e., to yield the corresponding ketolides, useful as antibiotics (see, e.g., U.S. patent application Serial Nos. 60/172,159, filed 17 Dec. 1999; 60/140,175, filed 18 June 1999; 60/172,154, filed 17 Dec. 1999; and 60/129,729, filed 16 Apr. 1999, each of which is incorporated herein by reference), or to yield the corresponding motilides (see U.S. provisional patent application Serial No. 60/183,338, filed 18 Feb. 2000, attorney docket no. 30062-30053.00, inventors G. Ashley *et al.*, incorporated herein by reference).

In 43 of the 46 transformants that produced polyketides in the illustrative library described herein, the isolated polyketides had structures expected of the mutation(s). However, as observed in corresponding single mutations of the *eryA* gene in the single-plasmid system, additional products were observed with certain mutations. In most cases, the rapAT2 domain in module 3 recognized and processed both malonyl- and methylmalonyl-CoA and gave the expected 8-nor analogs plus lesser amounts of the 8-methyl analogs. In a few cases, only the 8-methyl analogs were formed. The relaxed-specificity of rapAT2 appears to be module-dependent, because only the expected products were observed with the same rapAT2 sequence at modules 2 or 5 (see Ruan *et al.*, 1997, Acyltransferase domain substitutions in erythromycin polyketide synthase yield novel erythromycin derivatives, *J. Bacteriol.* 179: 6416-25, incorporated herein by reference).

Likewise, when the KR of module 5 was replaced by either the rapDH/KR4 or rapDH/ER/KR1 domains to give the expected 4,5-anhydro and 5-deoxy analogs, respectively, 5-keto analogs were formed in addition to the expected products. This possibly results from transfer of the beta-ketothioester intermediate from KR5 to ACP5 at a rate competitive with its reduction by the heterologous rapKR4 domain. Because aberrant products were not observed with

rapDH/KR4 at modules 2 or 6, the non-specificity appears to be module-dependent.

Finally, when the KR of module 2 was replaced with the rapDH/ER/KR1 domain to provide the 11-deoxy analogs, the 10,11-dehydro analogs were often observed as minor but significant products. Here, the intermediate is processed by the heterologous rapKR and DH domains in module 2, but transfer of the 10,11-dehydro intermediate to KS3 must be competitive with the ER-catalyzed reduction. Interestingly, with rapDH/ER/KR1 in module 2 and rapAT2 in module 3, the 10,11-dehydro by-products were not detected. Either the levels produced were too low for detection using the methods employed, or the aberrant dehydro intermediate of module 2 was not processed by module 3 containing the rapAT2 substitution.

Of the 18 transformants that did not produce polyketides at levels detectable in these experiments, two were double mutants and 16 were triple mutants; only one of these mutants was previously prepared in the single-plasmid system where it also failed to produce a detectable polyketide. As previously reported with the single-plasmid system, an increased number of mutations resulted in a decrease in yield to a level undetectable by the analytical method used.

A major advantage of the multiple plasmid system is that once multiple plasmids encoding functional mutants of PKS subunits are available, they can be rapidly combined with one or more additional mutants to expand the library of polyketides. In one example, a single Cys729Ala mutation at the KS1 domain of DEBS1 module 1 (see Jacobsen *et al.*, 1997, *supra*) was prepared, yielding the KS1 null mutation. The inactive KS1 prevents propagation of the starter unit and permits introduction of exogenous synthetic diketide thiol esters into positions 12 and 13 of the 14-membered macrolide product. This system was first developed using a single vector, plasmid pJRK2. Plasmid pJRK2 encodes the *eryAI*, *eryAII*, and *eryAIII* genes; the *eryAI* gene contained in the plasmid contains the KS1 null mutation. The KS1 null mutation prevents formation of the 6-deoxyerythronolide

B produced by the wild-type gene unless exogenous substrate is provided.

Plasmid pJRK2 and a process for using the plasmid to prepare novel 13-substituted erythromycins are described in PCT publication Nos. 99/03986 and 97/02358 and in U.S. patent application Serial Nos. 08/675,817, filed 5 July 1996; 08/896,323, 5 filed 17 July 1997; and 09/311,756, filed 14 May 1999, each of which is incorporated herein by reference. The exogenous substrates provided can be prepared by the methods and include the compounds described in PCT patent application No. PCT/US00/02397 (Attorney Docket No. 30062-20032.40) and U.S. patent application Serial No. 09/492,733 (Attorney Docket No. 30062-20032.00), 10 both filed 27 Jan. 2000, by inventors G. Ashley et al., and both of which claim priority to U.S. patent application Serial No. 60/117,384, filed 27 Jan. 1999, each of which is incorporated herein by reference.

The plasmid encoding the KS1 null allele of *eryAI* (Table 1) was introduced by co-transformation into *Streptomyces lividans* with the one *eryAII* mutant and 15 seven *eryAIII* mutants (Table 1) to provide 16 transformants. Treatment of each of these with a propyl-diketide N-acetylcysteine thioester, following the work of Jacobsen *et al.*, 1997, and the methodology of the patent applications, *supra*, provided eleven novel 13-propyl polyketide analogs (49-59, Fig. 3). Thus, the present invention provides these novel polyketides as well as the compounds 20 resulting from their modification by post-PKS tailoring enzymes (oxidases and glycosylases) or by synthetic chemical methods. To prepare these same PKSs by the single-plasmid system would have required preparation of 16 individual mutants rather than the single KS1 null mutant used in the present method.

In another example, the variants of *eryAI* and *eryAII* were used to prepare a 25 small library of 12-membered macrolactones. It was previously shown in the *eryA* single-plasmid system that omission of module 6, along with fusion of module 5 to the thioesterase domain of DEBS3 (Fig. 1A) results in formation of a 12-membered macrolactone. A truncated *eryAIII* gene containing module 5-TE (see Kao *et al.*, 1995, Manipulation of macrolide ring size by directed mutagenesis of a 30 modular polyketide synthase, *J. Am. Chem. Soc.* 117: 9105-9106, incorporated

herein by reference, and Table 1) was introduced into *Streptomyces lividans*, and the strain transformed with permutations of the four *eryAI* and two *eryAII* variants described above. Of the eight 12-membered lactones that could have been produced, five were observed (44-48). Compound 44 results from combining the 5 wild-type *eryAI* and *eryAII* genes with the module 5-TE construct, and has previously been prepared in the single-plasmid system; compounds 45-48 are novel products that more than double the number of known 12-membered macrolides. These novel macrolactones constitute an important aspect of the present invention.

10 Other uses of this multiple plasmid system are as follows. The expression and genetic engineering of very large PKS genes, such as those involved in the biosynthesis of rapamycin (14 modules) or rifamycin (10 modules), is readily achievable by this method. The ORFs for each of the subunits of these and other PKSs, such as the mixed NRPS-PKS for epothilone (see U.S. patent application 15 Serial No. 09/443,501, filed 19 Nov. 1999, and PCT patent application US99/27438, filed 19 Nov. 1999, each of which is incorporated herein by reference) could be cloned and expressed in the manner used here to greatly simplify genetic manipulations and the structure/function analysis. Thus, in this application of the present method, a naturally occurring polyketide can be 20 expressed in a recombinant host cell.

Similarly, it would be desirable to mix PKS genes from entirely different pathways to facilitate production of heterologous and hybrid PKSs, as preceded by the work of Li *et al.* involving hybrid erythromycin/picromycin and oleandomycin/picromycinPKS genes (see U.S. patent application Serial Nos. 25 09/320,878, filed 27 May 1999, and 09/428,517, filed 28 Oct. 1999; PCT patent publication No. 99/61599; and PCT patent application No. US99/24478, each of which is incorporated herein by reference). Such work could include extending the carbon chain by the addition of modules.

The PKS libraries generated could be leveraged and expanded by 30 introducing genes for tailoring enzymes that oxidize, hydroxylate, methylate,

acylate, glycosylate, or otherwise modify the product of the PKS or a modified polyketide, and genes encoding such enzymes could be employed using an additional vector in the multiple vector system. Various tailoring enzymes from different host organisms could be employed in the same system. Genes for such 5 tailoring enzymes can be obtained as described in the patent applications and publications referenced in the preceding paragraph and elsewhere herein. See also, U.S. Patent No. 5,998,194, incorporated herein by reference.

Finally, the method should be useful with any system consisting of multimodular proteins, such as the large family of non-ribosomal peptide 10 synthases, which produce many pharmaceutically important compounds such as anti-fungal compounds, anti-cancer compounds, and antibiotics. These important compounds are made by multifunctional synthetases, consisting of complexes of proteins containing between one and eleven modules, comparable to the modular PKSs (see Konz *et al.*, 1999, How do peptide synthase generate structural 15 diversity? *Chem. & Biol.* 6: 39-48, incorporated herein by reference).

The multi-plasmid technology enables the realization of the full potential of modular PKSs and NRPSs, and thus libraries containing a complete repertoire of polyketides and non-ribosomal peptides. The achievement of this objective requires only the construction of a limited number of highly expressing, 20 productive single mutants that will assure adequate polyketide production when the mutations are combined. Because all the elements for producing an extraordinarily large polyketide library are contained within this facile system, there is neither need nor benefit to embark on developing more complicated, less reliable systems to reach the same objective.

25 The following examples are given for the purpose of illustrating the present invention and shall not be construed as being a limitation on the scope of the invention or claims.

Example 1Construction of Expression Plasmids

In each vector, the *eryA* gene is expressed under the control of the upstream *actI* promoter and *actII*-ORF4 gene as previously described (see U.S. Patent No. 5,672,491 and Ziermann *et al.*, 2000, *supra*, both of which are incorporated herein by reference). For testing the high copy replicating plasmid possessing the pJV1 origin, the pB45 based *E. coli* shuttle vector pKOS025-32 was constructed by fusing pB45 with litmus 28 (New England Biolabs) at *Bgl*II and *Pst*I sites. Into pKOS025-32 the ca. 14-kb *Hind*III-*Xba*I fragment containing the *actI* promoter and *actII*-ORF4 gene was inserted followed by the *eryAII* gene to give pKOS025-35. The configuration of the components in the *Hind*III-*Xba*I fragment is shown in Fig. 2. The same *Hind*III-*Xba*I fragment was also cloned into shuttle vector pOSint1/Hygro (see Raynal *et al.*, 1998, Structure of the chromosomal insertion site for pSAM2: functional analysis in *Escherichia coli*, *Molecular Microbiology* 28: 333-342, incorporated herein by reference) to yield the *eryAII*/pSAM2-hyg plasmid, pKOS038-67.

Example 2Transfer of Mutation Cassettes into the Three-plasmid System

The plasmids containing *eryAI* mutations in module 2 were pKOS025-179 (AT2→rapAT2), pKOS038-1 (KR→rapDH/KR4) and pKOS038-3 (KR→rapDH/ER/KR1) and were made as follows. The *Pac*I-*Spe*I fragments containing the corresponding mutations were transferred into the plasmids described in Fig. 2 from plasmids pKOS008-41, pKOS015-56 and pKOS015-57, respectively (see McDaniel *et al.*, 1999, *supra*, and U.S. patent application Serial No. 09/429,349, filed 28 Oct. 1999, and PCT patent application US99/24483, filed 20 Oct. 1999, each of which are incorporated herein by reference). The plasmids containing the *eryAIII* mutations in module 5 were pKOS025-1831 (AT→rapAT2), pKOS025-1832 (KR→AT/ACP linker), pKOS025-1833 (KR→rapDH/KR4) and pKOS025-1834 (KR→rapDH/ER/KR1); and in module 6 were pKOS025-

1841(KR→rapDH/KR4), pKOS021-106 (KR→AT/ACP linker) and pKOS025-1842 (AT→rapAT2). These were constructed as follows. The *Bgl*III-*Eco*RI fragments containing the corresponding mutations were transferred into the plasmids described in Fig. 2 from plasmids pKOS006-188, pKOS016-12, pKOS006-178,

5 pKOS026-11b, pKOS011-25, pKOS011-13 and pKOS015-53, respectively (see McDaniel et al., 1999, *supra*, and U.S. patent application Serial No. 09/429,349, filed 28 Oct. 1999, and PCT patent application US99/24483, filed 20 Oct. 1999, each of which are incorporated herein by reference). Plasmid pKOS038-20 contains *eryAII* with the AT3→rapAT2 replacement in module 3 and was made

10 by transferring the mutation from a previously prepared sub-clone pKOS015-28 (see McDaniel et al., 1999, *supra*, and U.S. patent application Serial No. 09/429,349, filed 28 Oct. 1999, and PCT patent application US99/24483, filed 20 Oct. 1999, each of which are incorporated herein by reference).

15

Example 3

Streptomyces Transformation

Streptomyces lividans K4-114 and K4-155 (see U.S. patent application Serial No. 09/181,833, filed 28 Oct. 1998, and Ziermann et al., 1999, Recombinant polyketide synthesis in *Streptomyces*: engineering of improved host strain,

20 *BioTechniques* 26: 106-110, both of which are incorporated herein by reference) transformants were prepared according to standard methods (see Hopwood et al., 1985, *supra*) using apramycin (100 µg/mL), thiostrepton (50 µg/mL), and hygromycin (225 µg/mL) in the R5 protoplast regeneration plates. In the three-plasmid system for which *eryAII*/pSAM2-hyg replaced *eryAII*/SCP2*-hyg, *S.*

25 *lividans* was transformed sequentially with pKOS010-153, pKOS038-67, and pKOS021-30.

Example 4Diketide Feeding

The (2S, 3R)-2-methyl-3-hydroxyhexanoyl-N-acetylcysteamine (NAC) thioester (propyl diketide) was synthesized in accordance with the method 5 described in U.S. patent application Serial Nos. 60/117,384, filed 27 Jan. 1999, and Serial No. 09/492,733 (attorney docket no. 30062-20032.00), filed 27 Jan. 00, by the same inventors and claiming priority to the foregoing application. The *Streptomyces lividans* triple transformants containing the KS1 null allele of *eryAI* (see Jacobsen *et al.*, 1997, *supra*, and PCT patent publication Nos. 99/03986 and 10 97/02358, each of which is incorporated herein by reference) were cultured in 5 mL of R5 medium at 30°C for 6 days under appropriate antibiotic selection. On day 4 of the incubation, 300 µL of diketide solution (4.7 mg/mL in 10% DMSO) and 50 µL of pentanoic acid (2.5 mg/mL) were added to the culture.

15

Example 5Production and Analysis of Polyketide Analogs

The *Streptomyces lividans* triple transformants were cultured in 5 mL of R5 medium (see Hopwood *et al.*, 1985, *supra*) at 30°C for 6 days under appropriate antibiotic selection. The cultured solution was extracted with 2 x 5 mL of ethyl acetate and the organic layers were combined and concentrated. A 50 µL aliquot of the concentrates was analyzed by HPLC on a reverse phase C₁₈ column (4.6 mm x 15 cm, Beckman, Fullerton, CA) using a PE SCIEX API100 LC/MS based detector (Perkin-Elmer, Foster City, CA). Quantitative determination of polyketide yield was made with evaporative light scattering detection (Analtec model 500 ELSD, Deerfield, IL). The polyketides were identified by their mass spectrum and correspondence to the products expected or to known standards. Under the ionization conditions used, 6dEB and its analogs generate signature dehydration patterns. The yield of the 13-ethyl 6dEB analogs varied from 7 mg/L to less than 0.1 mg/L and the 13-propyl analogs were produced in a range of 0.2 20 to 20 mg/L. The yields of the 12-membered lactones were not determined.

The invention having now been described by way of written description and examples, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments and that the foregoing description and examples are for purposes of illustration and not limitation of the following claims.

Claims

1. A method for expressing a polyketide or non-ribosomal peptide in a host cell employing a multiplicity of recombinant vectors, which may be integrative or freely replicating, wherein each of the multiplicity of vectors 5 encodes a portion of the polyketide synthase or non-ribosomal peptide synthase that produces the polyketide or non-ribosomal peptide, said method comprising steps of introducing said vectors into said cell, and culturing said cell into which said vectors have been introduced under conditions such that said polyketide synthase or non-ribosomal peptide synthase is produced.

10

2. The method of Claim 1, wherein said vectors encode a polyketide synthase.

3. The method of Claim 2, wherein said polyketide synthase is selected 15 from the group consisting of DEBS, an oleandolide PKS, a picromycin PKS, an epothilone PKS, a megalomicin PKS.

4. The method of Claim 1, wherein said vectors encode a non-ribosomal peptide synthase.

20

5. The method of Claim 1, wherein at least one of the multiplicity of vectors encodes a protein that further modifies the polyketide or non-ribosomal peptide produced by said polyketide synthase or non-ribosomal peptide synthase.

25

6. The method of Claim 1, wherein at least one of said vectors replicates extrachromosomally in said host cell.

7. The method of Claim 1, wherein at least one of said vectors integrates into the chromosome of said host cell.

30

8. The method of Claim 1, wherein said host cell is a *Streptomyces* host cell.
9. The method of Claim 8, wherein said vector is a derivative of a vector selected from the group consisting of integrating vectors pSET152 and pSAM2 and extrachromosomally replicating vectors SCP2* and pJV1.
10. A compound selected from the group consisting of compounds shown in Figure 3 as compound nos. 29-43 and 45-59.
11. A compound selected from the group consisting of compounds obtainable by hydroxylation and/or glycosylation of compounds 29-43 and 45-59 of Figure 3.
12. The compound of Claim 11 that is a 14-membered macrolactone with a C-6 and/or C-12 hydroxyl and/or a C-3 and/or C-5 glycosyl.
13. The compound of Claim 12, wherein said glycosyl is either a desosaminyl residue at C-5 or a cladinosyl residue at C-3 or both.
14. The compound of Claim 10 that is compound number 29 or 30 of Figure 3.
15. The compound of Claim 10 that is compound number 31 or 32 of Figure 3.
16. The compound of Claim 10 that is compound number 33 or 34 of Figure 3.
17. The compound of Claim 10 that is compound number 35 or 36 of Figure 3.

18. The compound of Claim 10 that is compound number 37 or 38 of
Figure 3.

5 19. The compound of Claim 10 that is compound number 39 or 40 of
Figure 3.

20. The compound of Claim 10 that is compound number 41, 42, or 43 of
Figure 3.

1/3




Figure 1

2/3




Figure 2

3/3




Figure 3